Longeveron (LGVN) Appoints Than Powell as Chief Business Officer

Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company’s overall business strategy, Alzheimer’s disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program.

“We are delighted to have Than join Longeveron at this transformational time in the Company’s development,” said Wa’el Hashad, Chief Executive Officer at Longeveron. “With the recent completion of enrollment of our pivotal Phase 2 trial evaluating our stem cell therapy laromestorcel for HLHS, we are approximately 13 months from top-line data, which, if positive, would be the foundation for the company’s first Biological License Application (BLA) submission. Than’s experience across multiple pharmaceutical and biotechnology companies will help guide Longeveron’s efforts to build on the clinical success of laromestorcel to date through partnering strategy for Alzheimer’s disease and international strategy for HLHS.”

"I am thrilled to join Longeveron,” said Than Powell, Chief Business Officer at Longeveron. “The scientific rigor and ground-breaking innovation at the heart of Longeveron’s stem cell research is inspiring, especially as my family has been impacted by some of the diseases they are studying. I look forward to delivering on the Company’s mission and supporting the potential approval of stem cell therapies for patients and their families."

Mr. Powell has over 25 years of pharmaceutical and biotech leadership across multiple industry leading organizations, including GSK and Eli Lilly. Prior to Longeveron, Mr. Powell led Corporate Development & Strategy for Surescripts, ultimately resulting in the company’s acquisition by TPG. Before that role, Mr. Powell was founder and CEO of Epulate, a venture-backed health technology company focused on Transplant Immunology.

Mr. Powell holds a Bachelor of Arts in Economics from DePauw University and a Master of Business Administration from Stanford University, Graduate School of Business.

You May Also Be Interested In

• Silvercorp suspends China mines after new safety rules hit output
• Orvana buys adjacent Argentina claims for $1.2M, expanding Taguas
• Santacruz Silver reports employee fatality at Bolivia's Reserva mine